Moderna, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stéphane Bancel
- Full Time Employees
- 5,800
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 Binney Street Cambridge MA United States of America 02142
- IPO Date
- Dec 7, 2018
- CIK
- 0001682852
- Website
- modernatx.com
- Similar Companies
- Business
- Moderna, Inc. (MRNA) develops and commercializes messenger RNA (mRNA) medicines and vaccines for infectious diseases, oncology, rare diseases, and other therapeutic areas; its core products include Spikevax (mRNA-1273), the COVID-19 vaccine approved for individuals 18 years and older; mRESVIA (mRNA-1345), the respiratory syncytial virus (RSV) vaccine for adults 60 years and older approved in the U.S., Europe, Canada, and Qatar; and mNEXSPIKE (mRNA-1283), the next-generation COVID-19 vaccine approved in the U.S.; the company advances a pipeline of over 45 development programs, including seasonal influenza and combination flu/COVID vaccines, cytomegalovirus vaccine candidates, individualized neoantigen therapies (INTs) such as intismeran autogene for oncology, and rare disease treatments targeting conditions like glycogen storage disease type 1a, with 36 ongoing clinical trials encompassing nine Phase 2 and Phase 3 oncology studies. Founded in 2010 and headquartered in Cambridge, Massachusetts, with manufacturing facilities in Norwood, Massachusetts, Moderna operates globally, partnering with governments and organizations in the U.S., UK, Canada, Australia, and Europe to support research, development, and commercial supply. Recent developments include closing a five-year $1.5 billion non-dilutive term loan facility with Ares Management Credit Funds in November 2025 to enhance liquidity to $7.1-7.6 billion; launching a three-year business strategy targeting up to 10% revenue growth in 2026 through geographic expansion and new product launches, aiming to grow its seasonal vaccine franchise from three to six approved products by 2028; investing $140 million to expand its Norwood facility for onshoring drug product capabilities, completing end-to-end domestic mRNA manufacturing; and discontinuing three pipeline assets—mRNA-1010 (seasonal influenza), mRNA-1083 (influenza/COVID combo), and mRNA-3745 (glycogen storage disease type 1a)—to prioritize high-impact programs amid cost management.
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
Moderna stock jumps as pipeline progress and flu shot data lift sentiment
Short Squeeze Alert—Moderna Stock Surges on New Strategy
Is Moderna Stock a No-Brainer Buy After a Key FDA Win?
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
Stock Of The Day: Will The Moderna Rally Continue?
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism
Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major Catalyst
Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript
Moderna Science Day Highlights Expanding Potential of mRNA Platform
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts
Major Indexes Continue Lower as Chip Selloff Drags Nasdaq
Should You Buy Moderna Before Aug. 5?
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?